Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Animesh Sinha, Roland Klebe, Michael L Rekart, Jose Luis Alvarez, Alena Skrahina, et al.
…ll-oral bedaquiline, pretomanid, and linezolid (BPaL)-based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings. **METH…
John Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, Alberto Mendoza-Ticona, Samuel Pierre, et al.
**BACKGROUND:** Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to d…
Ma S, Jaipalli S, Larkins-Ford J, Lohmiller J, Aldridge BB, et al.
…-resistant strains has created a pressing need for new drug regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new regimens has been challenging due to the slow growth of the pathogen Mycobacterium tuberculosis (MTB), coupled with the large…
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, et al.
…ects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and carry significant toxicity. A shorter, less toxic and more efficacious regimen would improve outcomes for people with rifampicin-resistant tuberculosis. Methods T…
Ghimire S, Karki S, Maharjan B, Kosterink JGW, Touw DJ, et al.
Objectives The objectives of this study were to evaluate treatment in patients on current programmatic multidrug-resistant tuberculosis (MDR-TB) regimen and verify eligibility for the 9-month regimen and therapeutic drug monitoring (TDM). Methods We performed a retrospective char…
Martínez-Campreciós J, Aznar ML, Zacarias A, Terán R, Nindia A, et al.
Background Short all-oral regimens for Rifampicin-resistant tuberculosis (ShORRT) have been a turning point in the treatment of drug-resistant tuberculosis. Despite this, access to drugs, stockouts, or adverse effects may limit the use of the recommended regimens. Methods Pragmat…
Mariah Benedict Raj P, Ganta GK, Durai Singh C, Muthusamy R
…. This study aimed to estimate the efficacy of TB treatment regimens and their successful outcomes in a retrospective analysis carried out in a tertiary health care hospital. Materials and methods A retrospective analysis was carried out on the patients diagnosed with TB and trea…
Garg K, Kaur K, Gupta A, Chopra V, Kumari S
Introduction The launch of injectable shorter regimens under Programmatic Management of Drug Resistant Tuberculosis (PMDT) guidelines 2017 under Revised National Tuberculosis Control Program (RNTCP) was a welcome step as it decreased the duration of treatment significantly in Dru…
Kohler S, Kohler S, Sitali N, Achar J, Paul N
…ntroduction of new and often shorter tuberculosis (TB) drug regimens affects the cost of TB programmes. Methods We modelled drug purchase and import costs for 20-month, 9-month and 4- to 6-month TB drug regimens based on 2016-2020 treatment numbers from a TB programme in Karakalp…
Reza Yosofi A, Mesic A, Decroo T
…after standardized all-oral short (12 months or less) RR-TB regimens has not yet been systematically reviewed, which is the main objective of this review. Methods This is a systematic review and meta -analysis. PubMed, Web of Science and Google scholar databases were systematical…
Feng PI, Horne DJ, Wortham JM, Katz DJ
… for Disease Control and Prevention has recommended shorter regimens-12 weeks of isoniazid and rifapentine or 4 months of rifampin-because they have similar efficacy, better tolerability, and higher treatment completion than 6-9 months of isoniazid. The objective of this analysis…
Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, et al.
…erefore LTBI treatment is key for TB elimination. Treatment regimens for LTBI include self-administered daily isoniazid for 6 (6H) or 9 (9H) months, self-administered daily rifampicin plus isoniazid for 3 months (3RH), self-administered daily rifampicin for 4 months (4R) and week…
Mark Kosenko, Lilit Davtian, Ekaterina Iakovleva, Mukhammad Ashurov, Dmitrii Podgalo, et al.
…onths of isoniazid (9H) versus shorter rifamycin-containing regimens for treating latent tuberculosis infection (TBI) in children. **METHODS:** We systematically searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials to June 2025 for randomized, controlled …
Arto Yuwono Soeroto, Aga Purwiga, Hendarsyah Suryadinata, Bachti Alisjahbana, Afiatin Makmun, et al.
…tudy analyzed 170 DR-TB individuals treated with BPaLM/BPaL regimens at Hasan Sadikin General Hospital, a tertiary hospital in West Java, Indonesia from January 2024 to January 2025. Data were collected from the Indonesian National DR-TB registers. A successful treatment outcome …
Doan TN, Cao P, Emeto TI, McCaw JM, McBryde ES
Short-course regimens for multidrug-resistant tuberculosis (MDR-TB) are urgently needed. Limited data suggest that the new drug bedaquiline (BDQ) may have the potential to shorten MDR-TB treatment to less than 6 months when used in conjunction with standard anti-TB drugs. However…
Sarin R, Vohra V, Singla N, Singla R, Puri MM, et al.
…age regimen. Methods BDQ and DLM were used together to make regimens along with other drugs where four effective anti TB drugs could not be prescribed as per WHO recommendations. Patients were followed up for sputum smear and culture conversion and adverse events during the treat…
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, et al.
Background Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. Methods In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmon…
Victor Babawale, Clement Adesigbin, Corinne S Merle, Vanessa Veronese, Fatimata Bintou Sall, et al.
The introduction of significantly shorter, all-oral regimens has significantly shifted the management of drug-resistant tuberculosis (DR-TB) towards a more tolerable and patient-centred therapeutic approach that aims to enhance treatment adherence, clinical outcomes, and quality …
Keon Young Lee, Miri Hyun, Ji Yeon Lee, Hyun Ah Kim
…of drug-resistant tuberculosis (TB). Bedaquiline-containing regimens are recommended for multidrug-resistant pulmonary TB, but evidence regarding the optimal treatment for extrapulmonary manifestations such as spinal TB remains limited.Herein, we report two cases of drug-resistan…
Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, et al.
Objective In 2018, shorter treatment regimens (STR) for people with drug-resistant tuberculosis (DR-TB) were introduced in Tanzania and included kanamycin, high-dose moxifloxacin, prothionamide, high-dose isoniazid, clofazimine, ethambutol and pyrazinamide. We describe treatment …
Susanna Esposito, Valentina Fainardi, Beatrice Rita Campana, Gaia Giorgia Arnesano, Nicola Principi
…16 years with drug-susceptible TB treated with short-course regimens compared to standard therapy.A shorter treatment regimen, particularly 4-month courses, has been investigated as an alternative to standard therapy in the pediatric population with drug-susceptible TB. Children …
Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Subay S, et al.
…ucted to analyze the efficacy and safety between individual regimens containing bedaquiline with delamanid and bedaquiline without delamanid. Methods This was an observational analytic study with a retrospective design in MDR-TB patients treated with individual regimens containin…
Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, et al.
…pants were asked to vote for preferred preventive treatment regimens and discuss the reasons behind their choices. Coding followed a deductive approach based on prior research, with data-driven codes added. Results In total, 7 (44%) participants voted for 3 months isoniazid and r…
Tanneau L, Karlsson MO, Rosenkranz SL, Cramer YS, Shenje J, et al.
…Furthermore, we predicted the safety profiles of once daily regimens. Data were obtained from a trial where participants were randomized 1:1:1 to receive delamanid, bedaquiline, or delamanid + bedaquiline. The effect on QTcF of delamanid and/or its metabolite (DM-6705) and the ph…
Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, et al.
…lowed by 200 mg three times a week for 22 weeks. To compare regimens, patients were exactly matched on HIV and ART status, previous tuberculosis treatment history, and baseline acid-fast bacilli smear and culture result, while propensity score matched on age, sex, province of tre…